Evidence map›Paper›PMID 25237047›Full record

ArticleJournal of the American Heart Association2014

Circulating fibroblast growth factor-23 and the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities study.

Alvaro Alonso, Jeffrey R Misialek, John H Eckfeldt, Elizabeth Selvin, Josef Coresh, Lin Y Chen, Elsayed Z Soliman, Sunil K Agarwal, Pamela L Lutsey

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Heart Association, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Comprehensive assessment of novel cardiovascular biomarkers in AF.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Fibroblast Growth Factors in Cardiovascular Disease.Journal of atherosclerosis and thrombosis · 2024
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Serum magnesium, bone-mineral metabolism markers and their interactions with kidney function on subsequent risk of peripheral artery disease: the Atherosclerosis Risk in Communities Study.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2020
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Alvaro AlonsoDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN (A.A., J.R.M., P.L.L.).
Jeffrey R MisialekDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN (A.A., J.R.M., P.L.L.).
John H EckfeldtDepartment of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, MN (J.H.E.).
Elizabeth SelvinDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (E.S., J.C., S.K.A.).
Josef CoreshDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (E.S., J.C., S.K.A.).
Lin Y ChenDivision of Cardiovascular Sciences, University of Minnesota Medical School, Minneapolis, MN (L.Y.C.).
Elsayed Z SolimanEpidemiological Cardiology Research Center, Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC (E.Z.S.).
Sunil K AgarwalDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (E.S., J.C., S.K.A.).
Pamela L LutseyDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN (A.A., J.R.M., P.L.L.).
Johns Hopkins University · USUniversity of Minnesota · USUniversity of Minnesota Medical Center · USWake Forest University · US

Funding

Diabetes and Prediabetes in Older Adults in ARICR01DK089174 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI SELVIN, ELIZABETH · 2011 to 2020
$6.4M
Serum Vitamin D and Cardiovascular Disease Risk in the Biethnic ARIC CohortR01HL103706 · NHLBI · UNIVERSITY OF MINNESOTA · PI LUTSEY, PAMELA L. · 2011 to 2014
$2.3M
Epidemiologic Study of Risk Factors and Biomarkers of Atrial FibrillationRC1HL099452 · NHLBI · UNIVERSITY OF MINNESOTA · PI ALONSO, ALVARO · 2009 to 2010
$897k
NHLBI NIH HHS HHSN268201100005CNHLBI NIH HHS HHSN268201100005GNHLBI NIH HHS HHSN268201100005INHLBI NIH HHS HHSN268201100006CNHLBI NIH HHS HHSN268201100007CNHLBI NIH HHS HHSN268201100007INHLBI NIH HHS HHSN268201100008CNHLBI NIH HHS HHSN268201100008INHLBI NIH HHS HHSN268201100009CNHLBI NIH HHS HHSN268201100009INHLBI NIH HHS HHSN268201100010CNHLBI NIH HHS HHSN268201100011CNHLBI NIH HHS HHSN268201100011INHLBI NIH HHS HHSN268201100012CNHLBI NIH HHS R01 HL103706NHLBI NIH HHS RC1 HL099452NIDDK NIH HHS R01 DK089174
6 · The paper itself

Abstract

backgroundIncreased concentrations of circulating fibroblast growth factor 23 (FGF-23) have been associated with higher risk of cardiovascular disease. The association between FGF-23 and the risk of atrial fibrillation (AF), a common arrhythmia, is less defined. Thus, we explored whether FGF-23 concentration was associated with AF incidence in a large community-based cohort. METHODS AND

resultsWe studied 12 349 men and women enrolled in the Atherosclerosis Risk in Communities (ARIC) study, without prevalent AF at baseline in 1990-1992. Serum intact FGF-23 concentration was measured with the Kainos 2-site ELISA. Incident AF through 2010 was ascertained from study ECGs and hospital discharge codes. Cox proportional hazards models adjusted for potential confounding factors, including kidney function, were used to estimate the association between FGF-23 and AF risk. We identified 1572 AF events during a mean follow-up of 17 years. In multivariable analysis, a difference of 1 SD (16 pg/mL) in baseline FGF-23 was not associated with the risk of AF (hazard ratio [HR], 1.04; 95% confidence interval [CI], 0.99, 1.09). Results were similar when FGF-23 was modeled in quartiles (HR, 1.09; 95% CI, 0.94, 1.26, comparing extreme quartiles). Reduced kidney function was associated with increased AF risk across quartiles of FGF-23 levels.

conclusionIn this large community-based cohort, baseline FGF-23 levels were not associated with AF risk independently of kidney function. Our results do not support a major role for FGF-23 as a risk factor for AF or as a mediator of the association between chronic kidney disease and AF.

Indexed as

AgedAge DistributionAtherosclerosisAtrial FibrillationBiomarkersCardiovascular DiseasesCohort StudiesEnzyme-Linked Immunosorbent AssayFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsHumansMaleMiddle AgedPopulation SurveillancePredictive Value of TestsBiomarkersFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth Factorsatrial fibrillationepidemiologykidneyrisk factors

Identifiers

PMID25237047
PMCPMC4323781
OpenAlexW2101979840

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.